Deals Of The Week: Janssen/CorImmun, AstraZeneca/Cellworks, Ferring/Albireo
Executive Summary
To the familiar sounds of the Fourth of July and mid-summer, Deals of the Week adds another: the sound of the next shoe dropping in biopharmaceutical merger-and-acquisition activity. What happens next after the $5 billion-plus buyout of Amylin by Bristol-Myers?
You may also be interested in...
Deals Of The Week: Academic Drug-Discovery Group’s Work Catching Industry’s Notice
As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.
AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.
Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health
Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.